The resistance rates of urinary tract infections: Our data from year 2010

dc.authorid0000-0003-0398-9216
dc.contributor.authorDogru, Arzu
dc.contributor.authorKaratoka, Belma
dc.contributor.authorErgen, Pınar
dc.contributor.authorAydin, Ozlem Sen
dc.contributor.authorTigen, Elif Tukenmez
dc.date.accessioned2025-05-10T19:58:47Z
dc.date.issued2013
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractObjective: More than 95% of all urinary tract infections are caused by a single bacterium. Although E. coli is the most common bacterium causing community-acquired infections, Klebsiella spp., enteric gram-negative bacteria and S. saprophyticus have been also identified. This study evaluated the microorganisms isolated from the urine cultures of patients admitted to our outpatient clinics in 2010 and assessed E. coli resistance and the frequency of extended-spectrum beta lactamase (ESBL)-producing bacteria. Material and methods: In total, 7145 urine cultures were obtained from patients admitted to all clinics between 1 January 2010 and 31 December 2010. The double-disk synergy test was used to identify the presence of ESBL producers. Results: The most frequently isolated microorganisms were E. coli (60.6%), Enterococcus spp. (10.3%), Klebsiella spp. (7.3%), Pseudomonas spp. (4.8%), and Streptococcus spp. (3.3%). E. coli strains were more resistant to ciprofloxacin (45.12%), trimethoprim-sulfamethoxazole (44.8%) and amoxicillin-clavulanate (31.6%), but they were less likely to be resistant to meropenem (0%), imipenem (0.2%), and amikacin (0.7%). The frequency of ESBL-producing E. coli strains was 14%. Conclusion: The choice of antibiotic treatment influences the overall success of treatment and the development of resistance, and it is also closely related to the cost of the treatment. As a result, there is a need to review the current treatment protocols. As resistance rates show regional differences, it is necessary to regularly examine regional resistance rates to determine the appropriate empiric antibiotic treatment and reduce costs.
dc.identifier.doi10.5152/tud.2013.060
dc.identifier.endpage243
dc.identifier.issn2149-3235
dc.identifier.issn2149-3057
dc.identifier.issue4
dc.identifier.pmid26328117
dc.identifier.scopus2-s2.0-84885128005
dc.identifier.scopusqualityN/A
dc.identifier.startpage237
dc.identifier.trdizinid149963
dc.identifier.urihttps://doi.org/10.5152/tud.2013.060
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/149963
dc.identifier.urihttps://hdl.handle.net/20.500.14730/13652
dc.identifier.volume39
dc.identifier.wosWOS:000420579800006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAves
dc.relation.ispartofTurkish Journal of Urology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectE. coli
dc.subjectextended-spectrum beta lactamase
dc.subjecturine culture
dc.titleThe resistance rates of urinary tract infections: Our data from year 2010
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
13652.pdf
Boyut:
338.66 KB
Biçim:
Adobe Portable Document Format